Exploring the real-world use of trastuzumab emtansine in Ontario, Canada

Summary

Client: Hoffmann-La Roche Limited

Project ID: P2023-208/ 2025 0970 394 000

Research Question/Objectives: Kadcyla (trastuzumab emtansine) is a type of antibody-drug conjugate targeted therapy with two approved indications:

• Metastatic Breast Cancer (mBC)
  • Kadcyla (trastuzumab emtansine for injection) monotherapy is indicated for the treatment of HER2-positive metastatic breast cancer patients who received both prior treatment with trastuzumab and a taxane, separately or in combination.
• Early Breast Cancer (eBC)
  • Kadcyla monotherapy is indicated for the adjuvant treatment of HER2-positive early breast cancer patients who have residual invasive disease following neoadjuvant taxane and trastuzumab-based treatment.

Objectives:

Primary Objective:

• To characterize the frequency and percentage of trastuzumab emtansine use, by indication overall and quarter and Local Health Integration Network (LHIN) with number of cycles

Status: Completed

Results: September 2025